IP Library Granted Patent US 9,920,374
Granted Patent B2
US 9,920,374 · App. 14/613,210 · Granted Mar 20, 2018

Diagnostic for lung disorders using class prediction

Inventors: Jerome S. Brody (Boston, MA); Avrum Spira (Newton, MA); Jennifer E. Beane-Ebel (Fort Collins, CO); Marc E. Lenburg (Berkeley, CA)
Assignee: Trustees of Boston University
C12Q1/6886C12Q2600/158C12Q2600/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,920,374
App. No.
14/613,210
Granted
Mar 20, 2018
Kind
B2
Abstract

The present invention provides methods for diagnosis and prognosis of lung cancer using expression analysis of one or more groups of genes, and a combination of expression analysis with bronchoscopy. The methods of the invention provide far superior detection accuracy for lung cancer when compared to any other currently available method for lung cancer diagnostic or prognosis. The invention also provides methods of diagnosis and prognosis of other lung diseases, particularly in individuals who are exposed to air pollutants, such as cigarette or cigar smoke, smog, asbestos and the like air contaminants or pollutants.

Claims (16)

1. A method of processing a sample of airway epithelial cells from a subject who is asymptomatic for lung cancer, comprising:

(a) receiving a sample of airway epithelial cells from the subject who is asymptomatic for lung cancer; and

(b) measuring, by reverse-transcription polymerase chain reaction (RT-PCR) analysis, the expression level of gene transcripts in the sample, wherein the gene transcripts measured comprise IL-8, FOS, and BACH2.

2. The method of claim 1 wherein the gene transcripts measured further comprise DEFB1.

3. The method of claim 2 wherein the gene transcripts measured further comprise CCDC81.

4. The method of claim 1 further comprising measuring a gene transcript selected from Table 1.

5. The method of claim 1 further comprising measuring a gene transcript selected from Table 3.

6. The method of claim 1 further comprising measuring a gene transcript selected from Table 4.

7. The method of claim 1 further comprising measuring a gene transcript selected from Table 5.

8. The method of claim 1 further comprising measuring a gene transcript selected from Table 6.

9. The method of claim 1 further comprising measuring a gene transcript selected from Table 7.

10. The method of claim 1 wherein transcripts of at least 40 genes are measured.

11. The method of claim 1 wherein transcripts of at least 60 genes are measured.

12. The method of claim 1 wherein transcripts of at least 70 genes are measured.

13. The method of claim 1 wherein the airway epithelial cells are not from the bronchus.

14. The method of claim 1 wherein transcripts of no more than 180 genes are measured.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Nov 6, 2017
From: MADRYN HEALTH PARTNERS, LP
To: VERACYTE, INC.
Reel/Frame 044043/0880 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2017
From: BRODY, JEROME S.; SPIRA, AVRUM; BEANE, JENNIFER E.; LENBURG, MARC E.
To: TRUSTEES OF BOSTON UNIVERSITY
Reel/Frame 043723/0567 →
CHANGE OF NAME Recorded Mar 8, 2017
From: VISIUM HEALTHCARE PARTNERS, LP
To: MADRYN HEALTH PARTNERS, LP
Reel/Frame 041921/0799 →
SECURITY INTEREST Recorded Mar 30, 2016
From: VERACYTE, INC.
To: VISIUM HEALTHCARE PARTNERS, LP
Reel/Frame 038141/0852 →
RELEASE OF SECURITY INTEREST Recorded Mar 29, 2016
From: GALA THERAPEUTICS BVBA - SPRL
To: VERACYTE INC.
Reel/Frame 038126/0191 →
Continuity (5)
Continuation 13524749 · Jun 15, 2012
Continuation 12869525 · Aug 26, 2010
Continuation 11918588
Provisional Application 60671243 · Apr 14, 2005
Related Publication 20150354008A1 · Dec 10, 2015